UBS Group’s Processa Pharmaceuticals PCSA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $13.2K | Buy |
64,612
+64,556
| +115,279% | +$13.2K | ﹤0.01% | 7390 |
|
|
2025
Q1 | $21 | Sell |
56
-7,852
| -99% | -$2.95K | ﹤0.01% | 8770 |
|
|
2024
Q4 | $6.99K | Buy |
7,908
+7,387
| +1,418% | +$6.53K | ﹤0.01% | 7274 |
|
|
2024
Q3 | $714 | Buy |
+521
| New | +$714 | ﹤0.01% | 7624 |
|
|
2024
Q2 | – | Sell |
-4,181
| Closed | -$9.89K | – | 8662 |
|
|
2024
Q1 | $9.89K | Buy |
4,181
+180
| +4% | +$426 | ﹤0.01% | 6089 |
|
|
2023
Q4 | $26.8K | Buy |
4,001
+3,966
| +11,331% | +$26.6K | ﹤0.01% | 5714 |
|
|
2023
Q3 | $177 | Buy |
+35
| New | +$177 | ﹤0.01% | 7594 |
|
|
2023
Q2 | – | Sell |
-1,123
| Closed | -$11.2K | – | 8254 |
|
|
2023
Q1 | $11.2K | Buy |
+1,123
| New | +$11.2K | ﹤0.01% | 6429 |
|
|
2022
Q2 | – | Sell |
-56
| Closed | -$3K | – | 9586 |
|
|
2022
Q1 | $3K | Buy |
56
+45
| +409% | +$2.41K | ﹤0.01% | 8409 |
|
|
2021
Q4 | $1K | Sell |
11
-16
| -59% | -$1.46K | ﹤0.01% | 8876 |
|
|
2021
Q3 | $5K | Buy |
27
+25
| +1,250% | +$4.63K | ﹤0.01% | 7399 |
|
|
2021
Q2 | $0 | Buy |
+2
| New | – | ﹤0.01% | 8497 |
|